Vascular Alteration and Evolution of Cognitive Impairment (ADELAHYDE2)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In the cross sectional study "Adelahyde 1" which took place between 2001 and 2005, the investigators data suggest that vascular alterations may play a role in the setting of subjective memory complaints.
This longitudinal study (Adelahyde 2) aims to confirm the role of vascular factors in the evolution of cognitive function and dementia.
| Condition | Intervention |
|---|---|
|
Cognitive Impairment |
Other: blood sampling Procedure: brain MRI |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Arterial Function and Structure and Evolution of Cognitive Impairment in Elderly Hypertensive Subjects With Subjective Memory Complaints |
- composite score for Grober and Buschke (FCSR) [ Time Frame: up to two years ] [ Designated as safety issue: No ]
- vascular exploration [ Time Frame: up to two years ] [ Designated as safety issue: No ]Pulse wave velocity, VWF, IMT
- white matter hyperintensities by fazekas score. [ Time Frame: up to two years ] [ Designated as safety issue: No ]Hyperintensities of white matter will be classified following the Fazekas scale (6 ranks.
| Estimated Enrollment: | 200 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
-
Other: blood sampling
Background: The role of arterial hypertension and vascular alterations in the development of cognitive decline is a major issue in both research and clinical practice. In a recently published cross-sectional study (Kearney-Schwartz, Rossignol et al. 2009), conducted on the "ADELAHYDE" cohort comprised of older hypertensive patients with memory complaints, the investigators showed the association of arterial changes (hypertrophy and arterial stiffness, endothelial dysfunction) with cognitive functions and/or white matter hyperintensities on MRI. A longitudinal study is the only means to confirm the role of vascular factors in the evolution of cognitive function and onset of dementia.
Objectives: i) Primary: To establish, in the "ADELAHYDE" cohort, the relationship between vascular alterations assessed at baseline during the cross-sectional study (hypertrophy and arterial stiffness, endothelial dysfunction) and the evolution of cognitive function (primary study endpoint) over a 5-year follow-up period; ii) Secondary a) To investigate the evolution of white matter hyperintensities on MRI (secondary study endpoint) as a function of peripheral vascular status, and especially of endothelial function. b) Determine the role of genetic factors and biomarkers of oxidative stress (from DNA and serum biobanks collected at the first visit) in the evolution of cognitive functions and white matter hyperintensities.
Methods: Prospective longitudinal single center study. All patients (378 subjects) who participated in the baseline cross-sectional study conducted between 2003 and 2005, will be reconvened at the Clinical Investigation Centre (CIC) Nancy.
As in the cross-sectional study, the following will be assessed in this longitudinal phase: pulse wave velocity (PWV), carotid ultrasonography, flow-mediated dilation, brain MRI with semi-quantification of white matter hyperintensities, cognitive function evaluation and measurement of various biomarkers of endothelial function.
Expected fallouts: A major benefit of this project is that this cohort has already been explored in terms of cognitive function, arterial properties and neurovascular imaging (MRI). Thus, the programmed reconvening of these subjects for this project in 2010 will enable us to identify the role of vascular alterations in the evolution of cognitive function and leucoaraiosis in this population at high risk of dementia over a period of at least 5 years. Finally, it could pave the way for further investigations, notably in the field of cognitive impairment prevention, aimed at reducing or delaying the onset of dementia by acting on the "vascular factor", which is potentially modifiable.
Eligibility| Ages Eligible for Study: | 65 Years to 95 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patient who have participated Adelahyde 1 study
- patient who have signed a consent
- patient who have a social security
Exclusion Criteria:
- patient who can't understand information letter and who is not under legal protection
Contacts and Locations| Contact: Athanase BENETOS, Professor | +33 3 83 15 33 22 ext + 33 | a.benetos@chu-nancy.fr |
| France | |
| Chu Nancy | Recruiting |
| Nancy, France, 54500 | |
| Contact: Athanase Benetos, Professor | |
More Information
No publications provided
| Responsible Party: | Central Hospital, Nancy, France, Direction de la recherche et de l'innovation |
| ClinicalTrials.gov Identifier: | NCT01351961 History of Changes |
| Other Study ID Numbers: | 2010-A01399-30 |
| Study First Received: | April 22, 2011 |
| Last Updated: | May 10, 2011 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Central Hospital, Nancy, France:
|
Hypertension Cognitive function |
Additional relevant MeSH terms:
|
Cognition Disorders Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 22, 2013